IVERIC bio, Inc.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -13.92 | -40.20 | -35.29 | |
| Graham Fair Price | 1.37 | 6.35 | 6.27 | |
| PEG | -42.35 | 0.44 | 0.76 | |
| Price/Book | 39.29 | 6.99 | 5.02 | |
| Price/Cash Flow | -21.09 | -65.62 | -54.19 | |
| Prices/Earnings | 9.77 | -11.81 | -13.09 | |
| Price/Sales | 0.00 | 0.00 | 0.00 | |
| Price/FCF | -21.09 | -65.62 | -54.19 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | -49.72 | -0.12 | -0.08 | |
| ROE | -0.10 | -0.15 | -54.38 | |
| ROIC | -0.09 | -0.13 | -45.39 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.98 | -99.99 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.48 | -0.17 | 64.13 | |
| EPS QOQ | -0.17 | -0.27 | -56.50 | |
| FCF QOQ | -0.20 | -0.03 | 86.78 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.15 | 0.17 | 10.03 | |
| Quick Ratio | 18.18 | 15.24 | -16.17 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 4.27 | 3.48 | -18.42 | |
| Cash | 5.16 | 4.38 | -15.18 | |
| Capex | < 0.005 | < 0.005 | 28.01 | |
| Free Cash Flow | -0.40 | -0.37 | 6.16 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad